Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7NC and the C-cleavage site impact Gag-Pol processing by HIV-1 protease

Virology

Volumn 292, Issue 1, 2002, Pages 137-149

  Goodenow, Maureen M ^a   Bloom, Gregory ^a   Rose, Stephanie L ^a   Pomeroy, Steven M ^a   O'Brien, Patricia O ^a   Perez, Elena E ^a   Sleasman, John W ^a   Dunn, Ben M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; GAG PROTEIN; MATRIX PROTEIN; POL PROTEIN; POLYPROTEIN; PROTEINASE;

AMINO ACID SEQUENCE; ARTICLE; CASE REPORT; CELL KINETICS; CELL LINE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME POLYMORPHISM; FEMALE; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PROCESSING; PROTEIN VARIANT; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VIRUS NUCLEOCAPSID; VIRUS RECOMBINANT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036056291     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2001.1184     Document Type: Article

References (65)

1. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within GagPol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
2. A comparison of gag-pol precursor cleavage in naturally arising HIV variants
3. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
4. Guidelines for the use of antiretroviral agents in pediatric HIV infection
5. Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals
6. Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues
7. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA
8. Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation
9. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
10. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
11. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
12. Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions
13. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
14. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
15. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
16. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
17. Subsite preferences of retroviral proteases
18. HIV protease as a target for the design of antiviral agents for AIDS
19. Cleavage of HIV-1 gag polyprotein synthesized in vitro: Sequential cleavage by the viral protease
20. Genetic variability in HIV-1 in children treated by protease inhibitors
21. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing-hydrophobic*hydrophobic- or -aromatic*Pro- cleavage sites
22. Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen bond mutant A28S
23. Substrate cleavage by HIV-1 proteinase
24. Human immunodeficiency virus type 1 virions composed of unprocessed Gag and Gag-Pol precursors are capable of reverse transcribing viral genomic RNA
25. Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication
26. Functional domain mapping of HIV-1 Gag proteins
27. Active human immunodeficiency virus protease is required for viral infectivity
28. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides
29. Comparison of the human immunodeficiency virus type 1 and 2 proteases by hybrid gene construction and trans-complementation
30. A single 66-kilodalton polypeptide processed from the human immunodeficiency virus type 2 pol polyprotein in Escherichia coli displays reverse transcriptase activity
31. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects
32. Autoprocessing of HIV-1 protease is tightly coupled to protein folding
33. Proteolytic processing of HIV-1 protease precursor, kinetics and mechanism
34. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
35. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
36. An Escherichia coli expression assay and screen for human immuno-deficiency virus protease variants with decreased susceptibility to indinavir
37. Retroviral proteinases
38. Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein
39. Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase
40. Sequence specificity of retroviral proteases
41. Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI
42. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity
43. HIV-1 protease genotype predicts immune and viral response to combination therapy with protease inhibitors (PI) in PI-naïve patients
44. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions
45. Charged amino acid residues of human immunodeficiency virus type 1 nucleocapsid p7 protein involved in RNA packaging and infectivity
46. Transcriptional but not translational regulation of HIV-1 by the tat gene product
47. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2
48. Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor
49. Sequence requirements of the HIV-1 protease flap region determined by saturation mutagenesis and kinetic analysis of flap mutants
50. Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease
51. Retroviral proteases: First glimpses at the anatomy of a processing machine
52. Comparison of human immunodeficiency virus type 1 Pr55 (Gag) and Pr160 (Gag-Pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors
53. Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria
54. Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity
55. Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein
56. Kinetic analysis of human immunodeficiency virus type 1 assembly reveals the presence of sequential intermediates
57. The role of T3 in the activation of human T cells
58. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites
59. Structure-based inhibitors of HIV-1 protease
60. Mutations of the human immunodeficiency virus type 1 p6Gag domain result in reduced retention of Pol proteins during virus assembly
61. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo
62. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
63. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing